根据提供的文档内容，未包含具体的公司或行业分析信息，主要涉及分析师披露和免责声明等内容。因此，按照任务要求，跳过不相关的部分，不进行总结输出。 当前文档无实质性行业或公司研究内容可供提取关键要点 [1][2][3]

法律调查 - Bragar Eagel & Squire律师事务所正在调查GeneDx Holdings Corp可能违反联邦证券法的行为 [1] - 调查涉及GeneDx是否从事非法商业行为 [1] 欺诈指控 - Grizzly Research发布报告指控GeneDx通过欺诈手段虚增收入 [3] - 报告称GeneDx利用"代码堆叠"非法向医疗保险系统多收费 [3] - 公司CEO和CFO在股票解禁后立即抛售股票，从未在公开市场买入 [3] 市场反应 - 欺诈报告发布后GeneDx股价单日下跌4.84美元(6.72%)至67.18美元 [3] 投资者行动 - 律师事务所鼓励遭受损失的GeneDx投资者联系他们讨论法律选项 [1][4] - 投资者可通过电话(212) 355-4648或邮箱investigations@bespc.com联系律师 [4][7]

Key Takeaways WGS posted Q2 adjusted EPS of $0.50 vs. a loss of $0.08 last year; EPS beat estimates by 400%.WGS' revenues rose 45.6% to $102.7M, driven by 69% growth in exome and genome test revenues.Gross margin expanded 813 bps to 69% as WGS delivered its fourth straight profitable quarter.GeneDx Holdings Corp. (WGS) posted second-quarter 2025 adjusted diluted earnings per share (EPS) of 50 cents against a loss of 8 cents per share in the year-ago period. EPS surpassed the bottom-line estimate of 10 cents ...

GeneDx (WGS) Q2 2025 Earnings Call July 29, 2025 08:30 AM ET Company ParticipantsSabrina Dunbar - Director - IR & CommunicationsKatherine Stueland - CEO, President & DirectorKevin Feeley - CFOSubbu Nambi - Managing DirectorBrandon Couillard - Managing DirectorTycho Peterson - MD - Global EquitiesConference Call ParticipantsDavid Westenberg - MD & Senior Research AnalystDaniel Brennan - MD & Senior Equity Research AnalystWilliam Bonello - Senior Research AnalystMark Massaro - MD & Senior Equity Research Anal ...

GeneDx (WGS) Q2 2025 Earnings Call July 29, 2025 08:30 AM ET Speaker0Day and thank you for standing by. Welcome to the GeneDx Second Quarter twenty twenty five Earnings Conference Call. At this time, all participants are in a listen only mode. After the speakers' presentation, there will be a question and answer session. To ask a question during the session, you'll need to press 11 on your telephone.You will then hear an automated message advising your hand is raised. To withdraw your question, please press ...

公司业绩表现 - 季度每股收益0 5美元 远超Zacks一致预期的0 1美元 同比扭亏为盈(上年同期亏损0 11美元/股) [1] - 季度营收1 0269亿美元 超出市场预期21 24% 同比大幅增长45 67%(上年同期7051万美元) [2] - 连续四个季度均超市场EPS预期 最近两季度盈利超预期幅度分别达400%和154 55% [1][2] 股价与市场表现 - 年初至今股价累计上涨10 5% 跑赢标普500指数8 6%的涨幅 [3] - 当前Zacks评级为"买入"(Rank 2) 预计短期内将继续跑赢大盘 [6] 未来业绩展望 - 下季度EPS预期为0 3美元 营收预期9315万美元 全年EPS预期1 13美元 营收预期3 713亿美元 [7] - 盈利预测修正趋势向好 但需关注财报后预期调整方向 [6][7] 行业比较 - 所属医疗服务业在Zacks行业排名中位列前37% 历史数据显示前50%行业平均表现是后50%的2倍以上 [8] - 同业公司PACS Group预计季度EPS同比暴增742 9%至0 45美元 营收预期11 1亿美元(同比增长12 8%) [9]

GeneDx (Nasdaq: WGS) 2Q 2025 Earnings Presentation July 29, 2025 On average: 16 tests and 5 years before an accurate diagnosis Forward Looking Statements This presentation contains certain forward-looking statements within the meaning of the federal securities laws, including statements regarding our future performance, future operations, plans, objectives of management, and our market opportunity, including our expected full year 2025 reported revenue, volume, adjusted gross margin and adjusted net income. ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 Commission file number 001-39482 GeneDx Holdings Corp. 333 Ludlow Street, North Tower; 6th Floor Stamford, Connecticut 06902 (Address of Principal Executive Offices) (Zip Code) Registrant's telephone number, including area code: (888) 729-1206 Securities registered pursuant to Section 12(b) of ...

Exhibit 99.1 GeneDx Reports Second Quarter 2025 Financial Results and Business Highlights GAITHERSBURG, Md., July 29, 2025 — GeneDx Holdings Corp. (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic insights, today reported its financial results for the second quarter of 2025. "Crossing the $100 million revenue mark and delivering our fourth consecutive profitable quarter is a major milestone for GeneDx, putting us on a path for more growth at scale and enabling us to reach more p ...

Looking for a stock that has been consistently beating earnings estimates and might be well positioned to keep the streak alive in its next quarterly report? GeneDx Holdings Corp. (WGS) , which belongs to the Zacks Medical Services industry, could be a great candidate to consider.When looking at the last two reports, this company has recorded a strong streak of surpassing earnings estimates. The company has topped estimates by 202.27%, on average, in the last two quarters.For the last reported quarter, GENE ...